TAMPA, FL / ACCESS Newswire / April 8, 2025 / Dr. Thomas Rhee, a renowned sports chiropractor and medical innovator, is ...

Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to turn its focus toward autoimmune diseases. The move isn’t shocking ...

A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s Cellares has passed another major production milestone. Cellares ...

A study published in The Lancet Haematology has reported a 73% response rate for CAR T-cell therapy among patients with certain blood cancers. The clinical trials were conducted by researchers ...

AstraZeneca already has cell therapies in its pipeline, and it is now expanding its scope further with a deal to acquire EsoBiotec, a company in early clinical development with therapies made by ...

Chimeric antigen receptor (CAR) T-cell therapy is a promising field of cancer treatment that has shown great success in treating bloodborne cancers such as leukemia. It is a highly customized ...

I am also a board member of the French Society of Gene and Cell Therapy. I’m looking forward to introducing our ProTcell therapy platform’s recent advances and, more precisely, our efforts to ...

Cell programming biotech bit.bio is slimming its workforce by 25% as the company pivots to focus on biomedical tools instead of therapeutics development. The decision was driven by “shifting ...

Known as 'CAR T-cell therapy', the treatment involves modifying genes in one's T-cells -- a type of immune cells -- to help fight cancer. The study looked at patients with leukaemia, which occurs ...

Susan Galbraith, executive vice-president of oncology R&D at AstraZeneca, said the deal “has the potential to transform cell therapy and will enable us to scale these innovative treatments so ...

The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer many more patients access to transformative cell therapy treatments ...

But in December, Beauzile, 21, became the first person in New York State to be made symptom-free of sickle cell disease after undergoing Lyfgenia, a new type of gene therapy that uses stem cell ...